Risk-stratification in diffuse large B-cell lymphoma in the rituximab era

Introduction. Diffuse large B-cell lymphoma represents a group of entities characterized by pathological and biological heterogeneity different clinical outcomes. Due to pronounced heterogeneity, prognostic biomarkers are great importance in identifying high-risk patients who might benefit from more aggressive approaches or new therapeutic modalities. Several score systems have been established applied predict the survival with diffuse B-large cell lymphoma. The first system for NHL is International Prognostic Index, its variations Revised Index National Comprehensive Cancer Network- were subsequently introduced era immunochemotherapy. As discriminative power scores suboptimal, other strategies explored order improve risk stratification, especially highest treatment failure. In this regard, there tendency integrate genetic molecular somatic mutations into standardized personalized models stratification that would wide application routine practice. results recent studies based on machine learning methods shown best achieved combination clinical, parameters, as well parameters quantitative Positron Emission Tomography such Metabolic Tumor Volume dissemination features analysis circulating tumor DNA levels. This paper provides an overview which these analyzed.